Challenges for Nerve Repair Using Chitosan-Siloxane Hybrid Porous Scaffolds

Yuki Shirosaki, Satoshi Hayakawa, Akiyoshi Osaka, Maria A. Lopes, José D. Santos, Stefano Geuna, and Ana C. Mauricio

1 Frontier Research Academy for Young Researchers, Kyushu Institute of Technology, 2-4 Hibikino, Wakamatsu-ku, Kitakyushu 808-0196, Japan
2 Graduate School of Natural Science and Technology, Okayama University, 3-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan
3 CEMUC, Departamento de Engenharia Metálica e Materiais, Universidade do Porto, 4200-465 Porto, Portugal
4 Neuroscience Institute of the Cavalieri Ottolenghi Foundation, University of Turin, Regione Gonzole 10, 10043 Orbassano, Italy
5 Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, 10043 Orbassano, Italy
6 Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICRAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira No. 228, 4050-313 Porto, Portugal
7 Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares (ICETA), Rua D. Manuel II, Apartado 55142, 4051-401 Porto, Portugal

Correspondence should be addressed to Yuki Shirosaki; yukis@lsse.kyutech.ac.jp

Received 7 February 2014; Revised 29 May 2014; Accepted 31 May 2014; Published 17 June 2014

Academic Editor: Fausto Viterbo

Copyright © 2014 Yuki Shirosaki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The treatment of peripheral nerve injuries remains one of the greatest challenges of neurosurgery, as functional recovery is rarely satisfactory in these patients. Recently, biodegradable nerve guides have shown great potential for enhancing nerve regeneration. A major advantage of these nerve guides is that no foreign material remains after the device has fulfilled its task, which spares a second surgical intervention. Recently, we studied peripheral nerve regeneration using chitosan-\(\gamma\)-glycidoxypropyltrimethoxysilane (chitosan-GPTMS) porous hybrid membranes. In our studies, these porous membranes significantly improved nerve fiber regeneration and functional recovery in rat models of axonotmetic and neurotmetic sciatic nerve injuries. In particular, the number of regenerated myelinated nerve fibers and myelin thickness were significantly higher in rat treated with chitosan porous hybrid membranes, whether or not they were used in combination with mesenchymal stem cells isolated from the Wharton’s jelly of the umbilical cord. In this review, we describe our findings on the use of chitosan-GPTMS hybrids for nerve regeneration.

1. Introduction

Nerve regeneration is a complex biological process. While approaches for peripheral nerve repair have improved over the last few decades, functional recovery is usually incomplete. As a result, much attention has been given by researchers and clinicians to cell-based therapies and tissue engineering [1–4]. Autografts are commonly used to treat peripheral nerve damage caused by accidents or diseases; however, there are several disadvantages to this approach [5, 6]. In addition, although microsurgical techniques have substantially improved, peripheral nerve repair remains one of the greatest challenges of neurosurgery [2, 4, 7, 8]. Many basic research and clinical studies have demonstrated that entubulation promotes peripheral nerve reconstruction in neurotmetic injuries with a gap, permitting reconstruction of the defect without tension at the suture and creating a favorable microenvironment at the injury site. The implanted tube guides hasten Wallerian degeneration and promote regeneration from the lesioned proximal end without the disadvantages of a graft procedure. Over the last decade, many researchers have used artificial biomaterials to produce...
these tube guides [9–11]. Nerve cells can regenerate into the cylinder-shaped tubes, where the microenvironment promotes regeneration towards the distal nerve stump. These tube guides can be made of different biomaterials, and they allow the incorporation of various molecules and cellular systems [12]. The tube guides should be biocompatible, nontoxic, biodegradable, permeable, and noninflammatory, like other tissue engineering scaffolds. They should prevent fibrous scar tissue invasion but allow local revascularization to improve nutrient and oxygen supply. Consequently, appropriate biomaterial microporosity is fundamental to a positive clinical outcome [13–26]. The tube guides should also have an adequate mechanical strength to maintain a stable support structure for nerve regeneration over the healing period [27].

2. Nerve Conduits Prepared from Chitosan-Based Materials

Chitosan and its complexes have been studied for a number of biomedical applications, including wound dressings, drug delivery systems, and space-filling implants, because of their biocompatibility, biodegradability, wound-healing, and antibacterial properties [28]. Nerve conduits derived from chitosan have favorable mechanical properties and slow biodegradability. Many chitosan nerve conduits modified with other biodegradable polymers have been investigated by numerous laboratories. Optimal hydrophilicity has been found to be essential for preventing fibrous scar tissue invasion and for promoting nerve regeneration. Cheng et al. prepared chitosan-poly(L-lysine) composites and reported that their hydrophilic surfaces improved nerve cell affinity, showing better results compared with collagen [29]. Gelatin has also been blended with chitosan to improve elasticity and enhance nerve cell affinity [30]. Cell differentiation on chitosan films is also improved by blending with gelatin. Wang et al. succeeded in obtaining regeneration across a large nerve gap of 30 mm using chitosan-polyglycolic acid (PGA) [31]. The chitosan/PGA graft-reconstructed peripheral nerve allowed the restoration of nerve continuity and functional recovery, that is, locomotion, of the operated limb [31].

Chitosan nerve tube guides have also been modified by some research groups with inorganic components. For example, Görtner et al. prepared chitosan hollow tubes from crab tendons [32] and modified them with apatite to enhance mechanical strength, thereby preventing swelling. After implantation in a neurotmetic model of sciatic nerve injury with a 10 mm gap, the regenerated nerve tissues contained newly formed vessels, and macrophages were found to phagocytize the debris of the walls 4 weeks after surgery, demonstrating appropriate Wallerian degeneration, a crucial step toward regeneration.

Wallerian degeneration is the process of degeneration of the axon distal to the site of transection. Once a peripheral nerve has been transected, Wallerian degeneration of the distal axons begins and macrophages enter the area to remove the myelin and axonal debris. The surrounding basement membrane and Schwann cells play important roles in this process. Schwann cells line up along the basement membrane and synthesize growth factors that attract axonal sprouts formed at the terminal of the proximal segment of the severed axon [8]. Adding a cellular system capable of producing these important growth factors to a tube guide to direct nerve regrowth will also improve the first and essential stage of the regenerative process: Wallerian degeneration [32]. The basement membrane tubes and the artificial tube guides implanted using microsurgical techniques provide pathways for the regenerating axons to correctly innervate target muscles. The Schwann cells then remyelinate the newly formed axons; however, the newly formed myelin is thinner than normal and the newly formed internodes are shorter than normal [32].

Yamaguchi et al. [33, 34] modified chitosan/apatite composite tubes with laminin peptides to improve nerve regeneration [34]. The tubes incorporating laminin-1 and laminin peptides induced a more rapid regenerative response by improving the migration of Schwann cells and the bridging of axons. However, the recovery of nociceptive function was delayed compared with autograft treatment [34]. Chitosan-gold nanocomposite materials have also been studied and tested for use as nerve conduits [35]. The gold nanoparticles improved the mechanical strength of the chitosan. The gold in the composite affected the behavior of neural stem cells (NSCs) in vitro. Because NSCs are multipotent stem cells that can follow multiple differentiation pathways, using this differentiated cellular system may allow resident cell replacement and create an environment that supports and improves axon regeneration. The authors found that 50 ppm of gold nanoparticles stimulated cell proliferation and gene expression. After 6 weeks of implantation, a better and faster functional recovery was observed in animals treated with the chitosan-gold nanocomposite and NSCs compared with the composite alone in their model of neurotmetic injury with a gap. Histomorphometric analysis revealed that the number of myelinated axons in the regenerated nerve fibers was higher in animals where the nerve was reconstructed with the chitosan-gold nanocomposite and NSCs [35].

3. Challenges for Nerve Repair Using Chitosan-Siloxane Hybrids

Our group has synthesized inorganic-organic hybrids derived from chitosan and γ-glycidoxypropyltrimethoxysilane (GPTMS) units using sol-gel methods [36–42]. Different formats can be easily obtained, such as solid membranes, porous membranes, hydrogels, and tube guides. $^2$Si and $^{13}$C CP-MAS NMR analysis, FT-IR spectroscopy, ninhydrin assay, and contact angle analysis revealed the following physical characteristics of these hybrids [36, 38]: (1) the amino groups in chitosan reacted with the epoxy groups and interacted with silanol groups derived from GPTMS, (2) the silanol groups condensed to form 2D or 3D siloxane networks, and (3) some of the silanol groups remained in the hybrids and were orientated towards the surface of the structure.

The solid chitosan hybrid membranes allowed for good proliferation and differentiation of the human osteoblastic...
materials developed for nerve regeneration by implanting the surrounding microenvironment, including nutrient and pores, permit an adequate revascularization of the regenerating hybrid chitosan membranes, which have interconnected pores with a size between 50 and 150 μm. The porous hybrid chitosan membranes have interconnected pores with a size between 50 and 150 μm and a very high porosity, normally more than 85% [37]. The cells adhere on the pore walls with long and numerous pseudopodia and are able to proliferate and establish connections with each other even in the middle of the porous hybrid chitosan membranes [37].

Amado et al. studied nerve regeneration using solid and porous chitosan-GPTMS membranes in a standardized crush or axonotmetic injury of the rat sciatic nerve [44]. The 3 mm long axonotmetic lesion was wrapped with solid or porous chitosan-GPTMS membranes. Functional recovery was evaluated using the sciatic functional index, the static sciatic index, the extensor postural thrust (EPT), the withdrawal reflex latency (WRL), and ankle kinematics [45–48]. Nerve fiber regeneration was also assessed morphologically using quantitative stereological analysis and electron microscopy. The porous hybrid chitosan membrane significantly improved nerve fiber regeneration in their mode, assessed using functional and morphological criteria, in comparison with untreated animals or animals treated with the solid membrane. The numbers of fibers and axons and fiber size and myelin thickness were significantly improved in the chitosan porous membrane groups (Table 1). Functional recovery also improved during the healing period of 12 weeks, as evaluated using the EPT and WRL tests. The porous hybrid chitosan membranes, which have interconnected pores, permit an adequate revascularization of the regenerating tissue and help restore metabolic communication with the surrounding microenvironment, including nutrient and O₂ exchange [37]. These physicochemical properties help enhance nerve regeneration likely by promoting Schwann cell proliferation, neurite extension, and myelination [49–51].

Simões et al. tested the histocompatibility of the biomaterials developed for nerve regeneration by implanting the solid and porous membranes subcutaneously in the rat model. These membranes were subsequently used in experiments on sciatic nerve regeneration after axonotmetic and neurotmetic injuries [49]. The porous membranes induced a robust infiltration by multinucleated giant cells and some mast cells, whereas the solid membranes elicited mild fibrous capsule formation and a discrete inflammatory reaction. Differences in the inflammatory reaction might underlie the comparatively better regeneration obtained with the porous membranes. It should be noted that the porous membranes have a higher surface/volume ratio than the solid ones. Greater contact with the host immune system might cause the substantial cellular infiltration [49].

Simões et al. investigated the effect of the porous membranes in surgical neurotmetic repair either by direct suture, autograft, or tubulization and also compared a tube guide made of poly(lactide-co-glycolic) acid, where the two monomers, the lactic acid and the glycolic acid, were in a ratio of 90:10 (PLGA 90:10) [50]. As shown in Figure 1, the rats were divided into the following six experimental groups of six or seven animals each: Group 1, end-to-end neurorrhaphy wrapped by the porous membrane (End-to-EndChitIII); Group 2, 10 mm nerve gap bridged by an autologous nerve graft wrapped by the porous membrane (Graft180° ChitIII); Group 3, 10 mm nerve gap bridged by the porous membrane-like tube (GapChitIII); Group 4, 10 mm nerve gap bridged by an autologous nerve graft (Graft180°); Group 5, 10 mm nerve gap bridged by PLGA 90:10 tube guides (PLGA); and Group 6, end-to-end neurorrhaphy alone (End-to-End).

After 2 weeks, the WRL test had to be interrupted at the selected cut-off time of 12 s in all experimental animals in the different groups, except the ones in the End-to-End group. The recovery of WRL was faster in the End-to-End and End-to-EndChitIII groups during the healing period of 20 weeks. After 2 weeks, EPT commenced recovery and proceeded until week 20 to a similar extent in all groups, except in the PLGA group. In the groups with the porous chitosan-GPTM hybrids (End-to-EndChitIII, Graft180° ChitIII, and GapChitIII), the EPT recovery rate was faster than in the nonhybrids groups (End-to-End, Graft180°, and PLGA). Histomorphometric analysis of the nerves was performed after the healing period of 20 weeks, which showed that a good pattern of axon regeneration occurred in all treated groups; however, the pattern of regeneration in the PLGA group was comparatively inferior. In the GapChitIII group, nerve fibers regenerated along the chitosan tube guide, which helped establish an

| Group                          | Density (N/mm²) | Number (N) | Fiber diameter (mm) | Axon diameter (mm) | Myelin thickness (mm) |
|-------------------------------|-----------------|------------|---------------------|--------------------|-----------------------|
| Control                       | 10,123 ± 8,340  | 7,621 ± 198| 8.27 ± 0.29         | 5.34 ± 0.23        | 1.21 ± 0.05           |
| Crush                         | 18,452 ± 1,952  | 10,180 ± 964| 5.31 ± 0.34         | 4.12 ± 0.32        | 0.60 ± 0.08           |
| Solid membrane                | 17,196 ± 3,364  | 9,774 ± 359| 5.77 ± 0.45         | 4.54 ± 0.35        | 0.62 ± 0.06           |
| Porous membrane               | 14,210 ± 1,600  | 7,780 ± 1,053| 6.72 ± 0.26         | 5.00 ± 0.19        | 0.86 ± 0.05           |
| NEUROLAC                      |                 |            |                     |                    |                       |
| (commercial PLGA nerve guided tube) [31] | 21,982 ± 1,927 | 10,532 ± 2,195| 3.49 ± 0.11         | —                  | 0.40 ± 0.02           |
Six adult male Sasco Sprague-Dawley rats/group
10 mm gap in the sciatic nerve

| Procedure | Description |
|-----------|-------------|
| (1) End-to-End ChitIII | End-to-end neurorrhaphy enwrapped by chitosan membrane. |
| (2) Graft180° ChitIII | Nerve gap bridged by an autologous nerve graft enwrapped by chitosan membrane. |
| (3) GapChitIII | Nerve gap bridged by chitosan membrane. |
| (4) End-to-End | Only neurorrhaphy |
| (5) Graft180° | Nerve gap bridged by an autologous nerve graft. |
| (6) PLGA | Nerve gap bridged by an autologous nerve graft enwrapped by PLGA tube. |

**Figure 1:** Illustration of the surgical neurotmetic repair by direct suture, autograft, or tubulization.

extensive perineural connective architecture that contributed to axonal fasciculation. The neuroregenerative properties of the porous chitosan GPTMS might arise from its ability to promote the expression of myelin genes. The silica ions in the hybrid might induce expression of several glycoproteins, such as RCL, cyclin D1, and CD44. [52, 53]. Our results suggest that porous chitosan-GPTMS hybrids can be a valuable material for fashioning nerve guides aimed at bridging nerve defects.

Schwann cells, mesenchymal stem cells, embryonic stem cells, and marrow stromal cells have been extensively studied for their ability to promote nerve regeneration. We focused our research on the in vitro differentiated NIE-115 cell line [47–51] and on mesenchymal stem cells (MSCs) from the Wharton’s jelly of the umbilical cord [32]. In vivo experiments using the rat sciatic nerve model were performed using the porous hybrid chitosan membranes seeded with neuroglial-like cells obtained from in vitro differentiated NIE-115 cells. The combination of the porous hybrid membranes with these neuroglial-like cells was tested in axonotmetic and neurotometric injuries. The implantation of cultured cells (NIE-115 cells, MSCs, Schwann cells, and other cellular systems) into defective nerves can be achieved using two different techniques. The cellular system can be directly injected into the neural scaffold that has been interposed between the proximal and distal nerve stumps or around the crush injury (in neurotmetic and axonotmetic injuries, resp.). Alternatively, implantation can be achieved by preadding the cells to the neural scaffold via injection or coculture (in most of the cellular systems, it is allowed to form a monolayer), and then the biomaterial with the cellular system is implanted into the injured nerve [47–51]. The NIE-115 cell line is a mouse neuroblastoma cell line that can undergo neuronal differentiation in response to dimethylsulfoxide, adenosine 3′,5′-cyclic monophosphate, or serum withdrawal [51, 54]. The cellular system was tested in axonotmetic and neurotmetic lesions to locally produce and deliver neurotrophic factors, which are crucial for nerve regeneration. Also, this cellular system was used as an inexpensive and easy in vitro cultured model of stem cells [51, 54].

Simões et al., in 2010, used the rat sciatic nerve model for investigating the effect of porous hybrid chitosan membranes in a neurotmetic injury, used together with standard microsurgical repair methods (i.e., direct epineural end-to-end suture without tension, inverted autograft, and tubulization) [50]. Morphological analysis showed that nerve regeneration had occurred when the porous hybrid chitosan membrane was used in neurotmetic injuries. At week 20, it could be observed that Wallerian degeneration was complete and followed by the regrowth of axons and Schwann cell myelination. The results obtained with these membranes were significantly better, in terms of functional and morphological recovery, compared with PLGA 90:10, where regeneration was weak [50]. The favorable physicochemical properties of porous hybrid chitosan membranes compared with regular chitosan and the presence of silica might underlie their ability to enhance nerve regeneration [50]. The porous hybrid chitosan membranes might provide better mechanical support during nerve regeneration and, simultaneously, might work as an inducer of nerve regeneration, supporting the survival and ability of the Schwann cells to myelinate [50].

Light and electron microscopy analysis of PLGA 90:10 and chitosan tube guides containing in vitro differentiated NIE-115 cells suggested that the impairment in nerve fiber regeneration in these systems might have been caused by the presence of a large number of neuroblastoma-like cells colonizing large areas of the nerve profile, which might
have interfered with nerve regeneration inside the nerve guides. Interestingly, the presence of many blood vessels was observed inside the large neuroblastoma-like clusters, suggesting that transplanted cells can deprive the regenerating nerve fibers of blood supply \[46, 50\]. It should be noted that neurotrophic factors play an important role in nerve regeneration after injury or disease, and it is conceivable that if neurotrophic factors are applied in the close vicinity of the injured nerve, their healing potency is optimized. However, contrary to our initial hypothesis, the N1E-115 cells, in vitro differentiated into neuroglial-like cells, did not facilitate either nerve regeneration or functional recovery in neurotmetic injuries when used in combination with PLGA 90:10 or porous chitosan membranes. Indeed the presence of this cellular system reduced the number and size of the regenerated fibers, thus suggesting that this type of cellular system can partially impair nerve regeneration, at least from a morphological point of view. The impaired axonal regeneration seems to be the result of N1E-115 cells surrounding and invading the regenerating nerve, since many of these cells were seen colonizing the nerve and might have deprived the regenerating nerve fibers of blood supply. Taken together, these results suggested that the N1E-115 cells do not promote nerve healing, and their use might even impair nerve regeneration. For this reason, we started using human MSCs \[46, 50\].

Gärtner et al. seeded the porous membranes with undifferentiated human MSCs (hMSCs) isolated from Wharton’s jelly \[32\]. MSCs isolated from Wharton’s jelly are capable of being differentiated into multiple mesodermal cell types, including skeletal muscle and neurons \[55–57\], and therefore may be valuable for repairing the peripheral nervous system. In the study, the axonotmetic lesion of 3 mm in the rat sciatic nerve was wrapped with (1) the porous membrane or (2) the porous membrane covered with a monolayer of undifferentiated hMSCs or (3) was directly infiltrated with a suspension of hMSCs. WRL data showed a slightly delayed recovery in the porous membrane group compared with the other groups during the healing period of 12 weeks. In contrast, EPT performance was similar in all treated groups during the healing period. Fiber regeneration was good in all treated experimental groups. The regenerated nerves contained smaller myelinated fibers than normal nerves without injury, which is expected with axon regeneration (Table 2). The myelin thickness in the regenerated nerves was higher in groups wrapped with the porous membranes alone, confirming previous results \[44, 49, 52, 53\], or when the lesion site was directly infiltrated with undifferentiated hMSCs \[32\]. The negative effects observed with the neoplastic neuroblastoma-derived N1E-115 cell line \[44\] were not observed with hMSCs. hMSCs enhanced functional recovery by modulating the inflammatory reaction during Wallerian degeneration and by stimulating the production of growth factors. hMSCs may have an even more pronounced effect when applied to human injuries. Taken together, these findings demonstrate the therapeutic potential of hMSC and porous hybrid chitosan membranes in promoting myelin production in surgically reconstructed nerves after axonotmetic and neurotmetic injuries. These stem cells and hybrid porous chitosan membranes may also have clinical efficacy in neurodegenerative diseases that are typified by demyelination \[58\].

### Table 2: Histomorphometrical assessment of the regenerated rat sciatic nerve, treated with hMSCs and porous membranes, during a healing period of 12 weeks after axonotmetic injury.

| Group       | Density (N/mm²) | Number (N) | Fiber diameter (mm) | Axon diameter (mm) | Myelin thickness (mm) |
|-------------|-----------------|------------|---------------------|--------------------|----------------------|
| Crush       | 20,200 ± 4,971  | 9,806 ± 2,695 | 5.31 ± 0.19         | 3.74 ± 0.49        | 0.78 ± 0.10          |
| CrushCh     | 21,514 ± 6,308  | 11,413 ± 3,752 | 4.90 ± 0.97         | 3.41 ± 0.72        | 0.75 ± 0.14          |
| CrushChCell | 15,533 ± 7,713  | 7,982 ± 3,092       | 5.29 ± 1.05         | 3.50 ± 0.55        | 1.02 ± 0.22          |
| Control     | 15,905 ± 287    | 7,666 ± 190       | 6.66 ± 0.12         | 4.26 ± 0.07        | 1.19 ± 0.03          |

### 4. Conclusions

**In vivo** studies indicate that chitosan-GPTMS porous hybrid membranes are a very promising clinical tool in peripheral nerve reconstructive surgery. The combination of the chitosan-GPTMS porous hybrid membranes and hMSCs has a slight advantage in comparison to untreated controls. An enhancement of nerve regeneration was observed when hMSCs or the porous hybrid chitosan membranes were used alone but not when used in combination. An increase in myelin production, visible as higher myelin thickness measured by histomorphometry, was observed in surgically reconstructed nerves after axonotmetic and neurotmetic injury. These findings demonstrate the therapeutic potential of these cells and biomembranes in neurodegenerative diseases that are typified by demyelination. Further investigation using animal models is required to determine the efficacy of these systems in the treatment of critical nerve defects and neurodegenerative diseases.

### Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

### Acknowledgments

The authors would like to acknowledge the financial support from the Project TRIBONE, no. 11458, cofinanced by the European Community FEDER fund through ON2—O Novo Norte—the North Portugal Regional Operational...
References

[1] M. Samii, G. A. Carvalho, G. Nikkhah, and G. Penkert, “Surgical reconstruction of the musculocutaneous nerve in traumatic brachial plexus injuries,” *Journal of Neurosurgery*, vol. 87, no. 6, pp. 881–886, 1997.

[2] G. Lundborg, “Enhancing posttraumatic nerve regeneration,” *Journal of the Peripheral Nervous System*, vol. 7, pp. 139–140, 2002.

[3] S. Geuna, I. Papalia, and P. Tos, “End-to-side (terminolateral) nerve regeneration: a challenge for neuroscientists coming from an intriguing nerve repair concept,” *Brain Research Reviews*, vol. 52, no. 2, pp. 381–388, 2006.

[4] A. Höke, “Mechanisms of disease: what factors limit the success of peripheral nerve regeneration in humans?” *Nature Clinical Practice Neurology*, vol. 2, pp. 448–454, 2006.

[5] G. Lundborg, “Bridging nerve defects—the role of tissue inter-positioning,” in *Several Traumatic Defects of the Upper Limb*, A. C. Masquelet and A. C. Ferreira, Eds., pp. 153–167, Martin Dunitz, London, UK, 2003.

[6] T. Matsuyama, M. Mackay, and R. Midha, “Peripheral nerve repair and grafting techniques: a review,” *Neurologia Medico-Chirurgica*, vol. 40, no. 4, pp. 187–199, 2000.

[7] R. D. Madison, S. J. Archibald, and C. Krarup, “Peripheral nerve injury;” in *Wound Healing: Biochemical and Clinical Aspects*, I. K. Cohen, F. Diegelman, and W. J. Lindbald, Eds., pp. 450–487, W.B. Saunders, Philadelphia, Pa, USA, 1992.

[8] H. Millesi, “Progress in peripheral nerve reconstruction,” *World Journal of Surgery*, vol. 14, no. 6, pp. 733–747, 1990.

[9] W. F. den Dunnen, P. H. Robinson, R. van Wessel, A. J. Penninga, M. B. van Leeuwen, and J. M. Schakenraad, “Long-term evaluation of degradation and foreign-body reaction of subcutaneously implanted poly(DL-lactide-epsilon-caprolactone),” *Journal of Biomedical Materials Research*, vol. 36, pp. 337–346, 1997.

[10] C. E. Schmidt and J. B. Leach, “Neural tissue engineering: strategies for repair and regeneration,” *Annual Review of Biomedical Engineering*, vol. 5, pp. 293–347, 2003.

[11] B. Battiston, S. Geuna, M. Ferrero, and P. Tos, “Nerve repair by means of tubulization: literature review and personal clinical experience comparing biological and synthetic conduits for sensory nerve repair,” *Microsurgery*, vol. 25, no. 4, pp. 258–267, 2005.

[12] N. Suematsu, “Tubulation for peripheral nerve gap: its history and possibility,” *Microsurgery*, vol. 10, no. 1, pp. 71–74, 1989.

[13] M. H. Beigi, L. Ghasemi-Mobarakeh, M. P. Prabhakaran et al., “In vivo integration of poly(epsilon-caprolactone)/gelatin nanofibrous nerve guide seeded with teeth derived stem cells for peripheral nerve regeneration,” *Journal of Biomedical Materials Research Part A*, 2014.

[14] F. Cerri, L. Salvatore, D. Memon et al., “Peripheral nerve morphogenesis induced by scaffold micropatterning,” *Biomaterials*, vol. 35, pp. 4035–4045, 2014.

[15] J.-Y. Chang, T.-Y. Ho, H.-C. Lee et al., “Highly permeable genipin-cross-linked gelatin conduits enhance peripheral nerve regeneration,” *Artificial Organs*, vol. 33, no. 12, pp. 1075–1085, 2009.

[16] G. R. D. Evans, K. Brandt, M. S. Widmer et al., “In vivo evaluation of poly(l-lactic acid) porous conduits for peripheral nerve regeneration,” *Biomaterials*, vol. 20, no. 12, pp. 1109–1115, 1999.

[17] G. R. D. Evans, K. Brandt, A. D. Niederbichler et al., “Clinical long-term in vivo evaluation of poly(l-lactic acid) porous conduits for peripheral nerve regeneration," *Journal of Biomedical Materials Science, Polymer Edition*, vol. 11, no. 8, pp. 869–878, 2000.

[18] T. Hadlock, C. Sundback, D. Hunter, M. Cheney, and J. P. Vacanti, “A polyester foam conduit seeded with Schwann cells promotes guided peripheral nerve regeneration,” *Tissue Engineering*, vol. 6, no. 2, pp. 119–127, 2000.

[19] M. Karimi, E. Biazar, S. H. Keshel et al., “Rat sciatic nerve reconstruction across a 30 mm defect bridged by an oriented porous PHBV tube with schwann cell as artificial nerve graft,” *ASAIO Journal*, vol. 60, pp. 224–233, 2014.

[20] Y.-C. Lin, M. Ramadan, M. Hronik-Tupaj et al., “Spatially controlled delivery of neurotrophic factors in silk fibroin-based nerve conduits for peripheral nerve repair,” *Annals of Plastic Surgery*, vol. 67, no. 2, pp. 147–155, 2011.

[21] M. F. Meek and W. F. A. Den Dunnen, “Porosity of the wall of a Neurolac nerve conduit hampers nerve regeneration,” *Microsurgery*, vol. 29, no. 6, pp. 473–478, 2009.

[22] S. H. Oh, J. R. Kim, G. B. Kwon, U. Namgung, K. S. Song, and J. H. Lee, “Effect of surface pore structure of nerve guide conduit on peripheral nerve regeneration,” *Tissue Engineering C: Methods*, vol. 19, no. 3, pp. 233–243, 2013.

[23] S. C. Park, S. H. Oh, T. B. Seo, U. Namgung, J. M. Kim, and J. H. Lee, “Ultrasound-stimulated peripheral nerve regeneration within asymmetically porous PLGA/Pluronic F127 nerve guide conduit," *Journal of Biomedical Materials Research B: Applied Biomaterials*, vol. 94, no. 2, pp. 359–366, 2010.

[24] G. E. Rutkowski, C. A. Miller, S. Jeftinija, and S. K. Malapragada, “Synergistic effects of micropatterned biodegradable conduits and Schwann cells on sciatic nerve regeneration,” *Journal of Neural Engineering*, vol. 1, no. 3, pp. 151–157, 2004.

[25] Y. Yang, X. Gu, R. Tan et al., “Fabrication and properties of a porous chitin/chitosan conduit for nerve regeneration,” *Biotecnology Letters*, vol. 26, no. 23, pp. 1793–1797, 2004.

[26] B. Zavan, G. Abatangelo, F. Mazoleni, F. Bassetto, R. Cortivo, and V. Vindigni, “New 3D hyaluronan-based scaffold for in vitro regeneration of the rat sciatic nerve,” *Neurological Research*, vol. 30, no. 2, pp. 190–196, 2008.

[27] Y.-C. Huang and Y.-Y. Huang, “Biomaterials and strategies for nerve regeneration,” *Artificial Organs*, vol. 30, no. 7, pp. 514–522, 2006.

[28] T. Chandy and P. C. Charma, “Chitosan- as a biomaterial,” *Biomater Artif Cells Artif Organs*, vol. 18, pp. 1–24, 1990.

[29] M. Cheng, K. Gong, J. Li, Y. Gong, N. Zhao, and X. Zhang, “Surface modification and characterization of chitosan film blended...
with poly-L-lysine," *Journal of Biomaterials Applications*, vol. 19, no. 1, pp. 59–75, 2004.

[30] M. Cheng, J. Deng, F. Yang, Y. Gong, N. Zhao, and X. Zhang, “Study on physical properties and nerve cell affinity of composite films from chitosan and gelatin solutions,” *Biomaterials*, vol. 24, no. 17, pp. 2871–2880, 2003.

[31] X. Wang, W. Hu, Y. Cao, J. Yao, J. Wu, and X. Gu, “Dog sciatic nerve regeneration across a 30-mm defect bridged by a chitosan/PGA artificial nerve graft,” *Brain*, vol. 128, no. 8, pp. 1897–1910, 2005.

[32] A. Gärnert, T. Pereira, M. J. Simões et al., “Use of hybrid chitosan membranes and human mesenchymal stem cells from the Wharton jelly of umbilical cord for promoting nerve regeneration in an axonotmesis rat model,” *Neural Regeneration Research*, vol. 7, no. 9, pp. 2247–2258, 2012.

[33] I. Yamaguchi, S. Itoh, M. Suzuki, A. Osaka, and J. Tanaka, “The chitosan prepared from crab tendons: II. The chitosan/apatite composites and their application to nerve regeneration,” *Biomaterials*, vol. 24, no. 19, pp. 3285–3292, 2003.

[34] S. Itoh, I. Yamaguchi, M. Suzuki et al., “Hydroxyapatite-coated tendon chitosan tubes with adsorbed laminin peptides facilitate nerve regeneration in vivo,” *Brain Research*, vol. 993, no. 1–2, pp. 111–123, 2003.

[35] Y.-L. Lin, J.-C. Jen, S.-H. Hsu, and I.-M. Chiu, “Sciatic nerve repair by microgrooved nerve conduits made of chitosan-gold nanocomposites,” *Surgical Neurology*, vol. 70, no. 1, pp. S9–S18, 2008.

[36] Y. Shirosaki, K. Tsuru, S. Hayakawa et al., “In vitro cytocompatibility of MG63 cells on chitosan-organosiloxane hybrid membranes,” *Biomaterials*, vol. 26, no. 5, pp. 485–493, 2005.

[37] Y. Shirosaki, T. Okayama, K. Tsuru, S. Hayakawa, and A. Osaka, “Synthesis and cytocompatibility of porous chitosan-silicate hybrids for tissue engineering scaffold application,” *Chemical Engineering Journal*, vol. 137, no. 1, pp. 122–128, 2008.

[38] Y. Shirosaki, K. Tsuru, S. Hayakawa et al., “Physical, chemical and in vitro biological profile of chitosan hybrid membrane as a function of organosiloxane concentration,” *Acta Biomaterialia*, vol. 5, no. 1, pp. 346–355, 2009.

[39] Y. Shirosaki, C. M. Botelho, M. A. Lopes, and J. D. Santos, “Synthesis and characterization of chitosan-silicate hydrogel as resorbable vehicle for bonelike bone graft,” *Journal of Nanoscience and Nanotechnology*, vol. 9, no. 6, pp. 3714–3719, 2009.

[40] Y. Shirosaki, K. Tsuru, H. Moribayashi et al., “Preparation of osteocompatible Si(IV)-enriched chitosan-silicate hybrids,” *Journal of the Ceramic Society of Japan*, vol. 118, no. 1383, pp. 989–992, 2010.

[41] Y. Shirosaki, “Preparation of organic-inorganic hybrids with silicate network for the medical applications,” *Journal of the Ceramic Society of Japan*, vol. 120, no. 1408, pp. 555–559, 2012.

[42] Y. Shirosaki, T. Okayama, K. Tsuru, S. Hayakawa, and A. Osaka, “In vitro bioactivity and M63 cytocompatibility of chitosan-silicate hybrids,” *International Journal of Materials and Chemistry*, vol. 3, pp. 1–7, 2013.

[43] M. J. Coelho and M. H. Fernandes, “Human bone cell cultures in biocompatibility testing. Part II: effect of ascorbic acid, β-glycerophosphate and dexamethasone on osteoblastic differentiation,” *Biomaterials*, vol. 21, no. 11, pp. 1095–1102, 2000.

[44] S. Amado, M. J. Simões, P. A. S. Armada da Silva et al., “Use of hybrid chitosan membranes and NIE-115 cells for promoting nerve regeneration in an axonotmesis rat model,” *Biomaterials*, vol. 29, no. 33, pp. 4409–4419, 2008.

[45] A. L. Luis, S. Amado, S. Geuna et al., “Long-term functional and morphological assessment of a standardized rat sciatic nerve crush injury with a non-serrated clamp,” *Journal of Neuroscience Methods*, vol. 163, no. 1, pp. 92–104, 2007.

[46] A. L. Luis, J. M. Rodrigues, S. Amado et al., “PLGA 90/10 and caprolactone biodegradable nerve guides for the reconstruction of the rat sciatic nerve,” *Microsurgery*, vol. 27, no. 2, pp. 125–137, 2007.

[47] A. L. Luis, J. M. Rodrigues, S. Geuna et al., “Use of PLGA 90/10 scaffolds enriched with in vitro-differentiated neural cells for repairing rat sciatic nerve defects,” *Tissue Engineering A*, vol. 14, no. 6, pp. 979–993, 2008.

[48] A. L. Luis, J. M. Rodrigues, S. Geuna et al., “Neural cell transplantation effects on sciatic nerve regeneration after a standardized crush injury in the rat,” *Microsurgery*, vol. 28, no. 6, pp. 458–470, 2008.

[49] M. J. Simões, A. Gärnert, Y. Shirosaki et al., “In vitro and in vivo chitosan membranes testing for peripheral nerve reconstruction,” *Acta Médica Portuguesa*, vol. 24, pp. 43–52, 2011.

[50] M. J. Simões, S. Amado, A. Gärnert et al., “Use of chitosan scaffolds for repairing rat sciatic nerve defects,” *Italian Journal of Anatomy and Embryology*, vol. 115, no. 3, pp. 190–210, 2010.

[51] A. Amado, J. M. Rodrigues, A. L. Luis et al., “Effects of collagen membrane enriched with in vitro-differentiated NIE-115 cells on rat sciatic nerve regeneration after end-to-end repair,” *Journal of NeuroEngineering and Rehabilitation*, vol. 7, article 7, 2010.

[52] G. Kuhn, A. Lie, S. Wilms, and H. W. Müller, “Coexpression of PMP22 gene with MBP and P0 during de novo myelination and nerve repair,” *Glia*, vol. 8, no. 4, pp. 256–264, 1993.

[53] I. D. Xynos, A. J. Edgar, L. D. K. Buttery, L. L. Hench, and J. M. Polak, “Gene-expression profiling of human osteoblasts following treatment with the ionic products of Bioglass 45S5 dissolution,” *Journal of Biomedical Materials Research*, vol. 55, pp. 151–157, 2001.

[54] J. M. Rodrigues, A. L. Luis, J. V. Lobato et al., “Determination of the intracellular Ca2+ concentration in the NIE-115 neuronal cell line in perspective of its use for peripheric nerve regeneration,” *Bio-Medical Materials and Engineering*, vol. 15, no. 6, pp. 455–465, 2005.

[55] H.-S. Wang, S.-C. Hung, S.-T. Peng et al., “Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord,” *Stem Cells*, vol. 22, no. 7, pp. 1330–1337, 2004.

[56] A. J. Marcus and D. Woodbury, “Fetal stem cells from extra-embryonic tissues: do not discard,” *Journal of Cellular and Molecular Medicine*, vol. 12, no. 3, pp. 730–742, 2008.

[57] Y.-S. Fu, Y.-C. Cheng, M.-Y. A. Lin et al., “Conversion of human umbilical cord mesenchymal stem cells in Wharton’s Jelly to dopaminergic neurons in vitro: potential therapeutic application for Parkinsonism,” *Stem Cells*, vol. 24, no. 1, pp. 115–124, 2006.

[58] A. Gärnert, T. Pereira, M. J. Simões et al., “Use of hybrid chitosan membranes and human mesenchymal stem cells from the Wharton jelly of umbilical cord for promoting nerve regeneration in an axonotmesis rat model,” *Neural Regeneration Research*, vol. 7, no. 29, pp. 2247–2258, 2012.